Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV
Clinical Trials · 2025
DOI: 10.1177/17407745251338558 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Trials, 2025. Verfasst von Yu Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Hauptthemen laut MEDLINE: HIV Infections, Precision Medicine, Anti-HIV Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Evaluation of heterogeneity of treatment effect among participants in large randomized clinical trials may provide insights as to the value of individualizing clinical decisions. The effect modeling approach to predictive heterogeneity of treatment effect analysis offers a promising framework for heterogeneity of treatment effect estimation by simultaneously considering multiple patient characteristics and their interactions with treatment to predict differences in outcomes between randomized treatments. However, its implementation in clinical research remains limited and so we provide a detailed example of its application in a randomized trial that compared raltegravir-based vs darunavir/ritonavir-based therapy as initial antiretroviral treatments for people living with HIV.
Methods
The heterogeneity of treatment effect analysis used a two-step procedure, in which a working proportional hazards model was first selected to construct an index score for ranking the treatment difference for individuals, and then a second calibration step used a non-parametric kernel approach to estimate the true treatment difference for participants with similar index scores. Sensitivity and supplemental analyses were conducted to evaluate the robustness of the results. We further explored the impact of covariates on heterogeneity of treatment effect and the choice between treatments.
Results
The heterogeneity of treatment effect analysis showed that while there is a clear trend favoring raltegravir-based therapy over darunavir/ritonavir-based therapy for the vast majority of the target population, there were a small subset of patients, characterized by more advanced HIV disease status, for whom the choice between the two treatments might be equivocal.
Conclusions
Through this example, we illustrate how an exploratory heterogeneity of treatment effect analysis might provide further insights into the comparative efficacy of treatments evaluated in a randomized trial. We also highlight some of the issues in implementing and interpreting effect modeling analyses in randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
ORCID-Profile: Yu Zheng
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Zheng, Y., Currier, J. S., & Hughes, M. D. (2025). Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV. Clinical Trials. https://doi.org/10.1177/17407745251338558
Vancouver
Zheng Y, Currier JS, Hughes MD. Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV. Clinical Trials. 2025. doi:10.1177/17407745251338558
BibTeX
@article{Zheng2025,
author = {Zheng, Yu and Currier, Judy S and Hughes, Michael D},
title = {Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV},
journal = {Clinical Trials},
year = {2025},
doi = {10.1177/17407745251338558}
}
EUVIMED